Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Amgen BiTEs Back Micromet-Developed Boehringer Antibody

Executive Summary

Cancer immunotherapy biotech Leap, backed by HealthCare Ventures and Lilly, reverse-merges with Israel's Macrocure. Elite and SunGen will partner to develop generic versions of four drugs that posted $3bn in aggregate sales over a recent 12-month stretch.

Advertisement

Related Content

Amgen's Cancer Strategy: A Multitude Of Modalities In Immuno-Oncology And Beyond
The NASH Pipeline: Replete With Targets And New Compounds
Conatus' Liver Focus Goes Well Beyond NASH
Macrocure's CureXcell Phase III Leg Ulcer Study Futile
Amgen Gobbles Up Micromet In $1.16 Billion BiTE
Exalenz Of Israel, Pfizer Of U.S. In Deal With FDA-Approved Test Kit

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097212

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel